Medexus Patent-Cliff Exposure & CMS Drug Spending Portfolio

Medexus (US): 4 reconciled FDA prescription therapies, $34.4M 2024 CMS Part D & Medicaid spend, and $3,050 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterUS
Reconciled FDA Portfolio Therapies4
2025 to 2030 Patent-Cliff Revenue Exposure0.0%
Primary Portfolio LOE Date2029-01-01
2024 CMS Total Public Spend$34.4M
2024 Medicare Part D Spend$22.5M
2024 Medicaid Spend$11.9M
California HCAI SB 17 FilingsSpecialty launch notice ($3,050 intro WAC)